Background: Bladder cancer accounts for almost 54% of urinary system cancer and is the
second most frequent cause of death in genitourinary malignancies after prostate cancer. About 70% of
bladder tumors are non-muscle-invasive, and the rest are muscle-invasive. Recurrence of the tumor is
the common feature of bladder cancer. Chemotherapy is a conventional treatment for MIBC, but it cannot
improve the survival rate of these patients sufficiently. Therefore, researchers must develop new
therapies. Antibody-based therapy is one of the most important strategies for the treatment of solid tumors.
Selecting a suitable target is the most critical step for this strategy.
Objective: The aim of this study is to detect therapeutic cell surface antigen targets in bladder cancer
using data obtained by proteomic studies.
Methods: Isobaric tag for relative and absolute quantitation (iTRAQ) analysis had identified 131 overexpressed
proteins in baldder cancer tissue and reverse-phase proteomic array (RPPA) analysis had
been done for 343 tumor tissues and 208 antibodies. All identified proteins from two studies (131+208
proteins) were collected and duplicates were removed (331 unique proteins). Gene ontology study was
performed using gene ontology (GO) and protein analysis through evolutionary relationships (PANTHER)
databases. The Human Protein Atlas database was used to search the protein class and subcellular
location of membrane proteins obtained from the PANTHER analysis.
Results: Membrane proteins that could be suitable therapeutic targets for bladder cancer were selected.
These included: Epidermal growth factor receptor (EGFR), Her2, Kinase insert domain receptor (KDR),
Heat shock protein 60 (HSP60), HSP90, Transferrin receptor (TFRC), Activin A Receptor Like Type 1
(ACVRL1), and cadherin 2 (CDH2). Monoclonal antibodies against these proteins or their inhibitors
were used for the treatment of different cancers in preclinical and clinical trials.
Conclusion: These monoclonal antibodies and inhibitor molecules and also their combination can be
used for the treatment of bladder cancer.